Literature DB >> 17384080

Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients.

Amit Gaggar1, Yao Li, Nathaniel Weathington, Margaret Winkler, Michele Kong, Patricia Jackson, J E Blalock, J P Clancy.   

Abstract

Matrix metalloproteases (MMPs) are proteolytic enzymes that regulate extracellular matrix turnover and aid in restoring tissue architecture following injury. There is an emerging role for extracellular matrix destruction in the pathogenesis of chronic neutrophilic lung diseases. In this study, we examined the expression and activity profiles of MMPs in lower airway secretions from cystic fibrosis (CF) patients, patients with acute respiratory failure (ARF), and normal controls. A discrete repertoire of MMP isoforms was found in the CF samples, with robust MMP-9 expression compared with normal controls and ARF. CF samples possessed increased levels of active MMP-9, as well as decreased amounts of tissue inhibitor of metalloprotease-1 (TIMP-1), a natural inhibitor of MMP-9. The CF inpatient samples demonstrated fully active MMP-9 activity compared with CF outpatients, ARF, and normal controls. CF samples also demonstrated increased human neutrophil elastase (HNE) levels compared with ARF and normal controls. To examine potential mechanisms for the protease dysregulation seen in the CF clinical samples, in vitro studies demonstrated that HNE could activate pro-MMP-9 and also degrade TIMP-1; this HNE-based activation, however, was not seen with MMP-8. A strong correlation was seen between HNE and MMP-9 activity in CF inpatient samples. Finally, the dysregulated MMP-9 activity seen in CF inpatient sputum samples could be significantly reduced by the use of MMP-9 inhibitors. Collectively, these findings further emphasize the proposed protease/antiprotease imbalance in chronic neutrophilic lung disease, providing a potential mechanism contributing to this proteolytic dysregulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384080     DOI: 10.1152/ajplung.00492.2006

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  47 in total

1.  CD14 signaling reciprocally controls collagen deposition and turnover to regulate the development of lyme arthritis.

Authors:  Bikash Sahay; Anju Singh; Arumugam Gnanamani; Rebeca L Patsey; J Edwin Blalock; Timothy J Sellati
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation.

Authors:  Amanda Cobos-Correa; Johanna B Trojanek; Stefanie Diemer; Marcus A Mall; Carsten Schultz
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

3.  Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen.

Authors:  Philip J O'Reilly; Matthew T Hardison; Patricia L Jackson; Xin Xu; Robert J Snelgrove; Amit Gaggar; F Shawn Galin; J Edwin Blalock
Journal:  J Neuroimmunol       Date:  2009-10-28       Impact factor: 3.478

Review 4.  The matrikine PGP as a potential biomarker in COPD.

Authors:  Mojtaba Abdul Roda; Amanda M Fernstrand; Frank A Redegeld; J Edwin Blalock; Amit Gaggar; Gert Folkerts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-10       Impact factor: 5.464

5.  The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation.

Authors:  Matthew T Hardison; F Shawn Galin; Christopher E Calderon; Uros V Djekic; Suzanne B Parker; Keith M Wille; Patricia L Jackson; Robert A Oster; K Randall Young; J Edwin Blalock; Amit Gaggar
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 6.  Interfering with extracellular matrix degradation to blunt inflammation.

Authors:  Philip J O'Reilly; Amit Gaggar; J Edwin Blalock
Journal:  Curr Opin Pharmacol       Date:  2008-03-17       Impact factor: 5.547

7.  Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation.

Authors:  Amit Gaggar; Steven M Rowe; Hardision Matthew; J Edwin Blalock
Journal:  Open Respir Med J       Date:  2010-03-30

8.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

9.  Matrix metalloproteinase activity in pediatric acute lung injury.

Authors:  Michele Y F Kong; Amit Gaggar; Yao Li; Margaret Winkler; J Edwin Blalock; J P Clancy
Journal:  Int J Med Sci       Date:  2008-12-16       Impact factor: 3.738

10.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.